Senators grilled Robert F. Kennedy Jr. on if and how he would reform Medicaid and Medicare during his first confirmation ...

The Centers for Medicare and Medicaid Services ("CMS") published a final notice outlining the processes and procedures for the Transitional ...

Biden-era policies rescinded by Donald Trump could signal a significant shake-up in Medicare and Medicaid drug price reforms.

The exact scope and duration is clear, and one question is what will happen to release of CDC data that employers and insurers use in pricing.

Of the scores of day-one executive orders (EOs) issued by President Trump, the order rescinding a Biden administration executive order on ...

And to ensure the safety of consumers, The US Food and Drug Administration announced big changes to lower the risk certain viruses will end up in your fresh and frozen berries. The change in ...

In 2025, we may see radical top-down changes to our healthcare system as new heads of the NIH – National Institutes of Health ...

these products are not considered generic versions and are not approved by the Food and Drug Administration. CMS had until Feb. 1 to publish the next round of drugs chosen for Medicare negotiation.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...

The IRA’s price controls discourage post-marketing research. The potential benefits from expanding access to the drug to ...